GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges

• Type of Material: Poster
• Authors: H Robinson, GeoVax Inc; S Kannanganat, Emory University; Sailaja Gangadhara, Emory University; Lilin Lai, Emory University; Tianwei Yu, Emory University; P Kozlowski, Louisiana State University; P Earl, National Institute of Allergy and Infectious Diseases; B Moss, National Institute of Allergy and Infectious Diseases; Rama Amara, Emory University
• Language: English
• Date: 2012-09-13
• Publisher: Emory University Libraries
• Copyright Statement: ©2012 Robinson et al; licensee BioMed Central Ltd.
• License: Creative Commons Attribution 2.0 Generic
• Final Published Version (URL): https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-9-S2-P25
• Conference or Event Name: From AIDS Vaccine 2012 Boston, MA, USA. 9-12 September 2012
• Keywords: Virology; Life Sciences & Biomedicine; Science & Technology
• Research Categories: Biology, Virology; Health Sciences, Public Health

Abstract

In 2010 we reported prevention of acquisition of a repeated SIVE660 challenge in rhesus macaques vaccinated with a SIV239 DNA/MVA vaccine that co-expressed GM-CSF and VLP in the DNA prime. The reduced risk of infection correlated with the avidity of Env-specific IgG. Here we report studies on the longevity and breadth of this protective response.